Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Taspoglutide versus pioglitazone in type 2 diabetes inadequately controlled on sulfonylurea with or without metformin
2009-009157-24Phase 3Terminated
- Sponsor
- Roche
- Start
- Apr 2009
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of taspoglutide in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Roche. Primary endpoint: Absolute change from baseline in HbA1c after 24 weeks. Started Apr 2009; status: terminated.
02
Drugs
taspoglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2009-009157-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-009157-24.